Title: Aarkstore - Primary Biliary Cirrhosis - Pipeline Review, H2 2014
1Primary Biliary Cirrhosis - Pipeline Review, H2
2014
Pharmaceutical and Healthcare Market Research
Report
2Summary
- Primary Biliary Cirrhosis - Pipeline Review, H2
2014, provides an overview of the Primary Biliary
Cirrhosiss therapeutic pipeline. - This report provides comprehensive information
on the therapeutic development for Primary
Biliary Cirrhosis, complete with comparative
analysis at various stages, therapeutics
assessment by drug target, mechanism of action
(MoA), route of administration (RoA) and molecule
type, along with latest updates, and featured
news and press releases. It also reviews key
players involved in the therapeutic development
for Primary Biliary Cirrhosis and special
features on late-stage and discontinued
projects.Global Markets Directs report features
investigational drugs from across globe covering
over 20 therapy areas and nearly 3,000
indications. The report is built using data and
information sourced from Global Markets Directs
proprietary databases, Company/University
websites, SEC filings, investor presentations and
featured press releases from company/university
sites and industry-specific third party sources,
put together by Global Markets Directs team. Drug
profiles/records featured in the report undergoes
periodic updation following a stringent set of
processes that ensures that all the profiles are
updated with the latest set of information.
3Scope
- The report provides a snapshot of the global
therapeutic landscape of Primary Biliary
Cirrhosis- The report reviews key pipeline
products under drug profile section which
includes, product description, MoA and RD brief,
licensing and collaboration details other
developmental activities - The report reviews
key players involved in the therapeutics
development for Primary Biliary Cirrhosis and
enlists all their major and minor projects- The
report summarizes all the dormant and
discontinued pipeline projects - A review of the
Primary Biliary Cirrhosis products under
development by companies and universities/research
institutes based on information derived from
company and industry-specific sources- Pipeline
products coverage based on various stages of
development ranging from pre-registration till
discovery and undisclosed stages- A detailed
assessment of monotherapy and combination therapy
pipeline projects - - Coverage of the Primary Biliary Cirrhosis
pipeline on the basis of target, MoA, route of
administration and molecule type- Latest news
and deals relating related to pipeline products
4Reasons to buy
- - Provides strategically significant competitor
information, analysis, and insights to formulate
effective RD development strategies- Identify
emerging players with potentially strong product
portfolio and create effective counter-strategies
to gain competitive advantage- Develop strategic
initiatives by understanding the focus areas of
leading companies- Identify and understand
important and diverse types of therapeutics under
development for Primary Biliary Cirrhosis- Plan
mergers and acquisitions effectively by
identifying key players of the most promising
pipeline- Devise corrective measures for
pipeline projects by understanding Primary
Biliary Cirrhosis pipeline depth and focus of
Indication therapeutics- Develop and design
in-licensing and out-licensing strategies by
identifying prospective partners with the most
attractive projects to enhance and expand
business potential and Scope- Modify the
therapeutic portfolio by identifying discontinued
projects and understanding the factors that drove
them from pipeline
5Table of Content
- Global Markets Direct Report Coverage 6Primary
Biliary Cirrhosis Overview 7Therapeutics
Development 8Pipeline Products for Primary
Biliary Cirrhosis - Overview 8Pipeline Products
for Primary Biliary Cirrhosis - Comparative
Analysis 9Primary Biliary Cirrhosis -
Therapeutics under Development by Companies
10Primary Biliary Cirrhosis - Pipeline Products
Glance 12Late Stage Products 12Clinical Stage
Products 13Early Stage Products 14Primary
Biliary Cirrhosis - Products under Development by
Companies 15Primary Biliary Cirrhosis -
Companies Involved in Therapeutics Development
16AlbireoPharma 16Dr. Falk Pharma GmbH
17GlaxoSmithKline plc 18Intercept
Pharmaceuticals, Inc. 19Johnson Johnson 20
6List of Tables
- Number of Products under Development for Primary
Biliary Cirrhosis, H2 2014 8Number of Products
under Development for Primary Biliary Cirrhosis -
Comparative Analysis, H2 2014 9Number of
Products under Development by Companies, H2 2014
11Comparative Analysis by Late Stage
Development, H2 2014 12Comparative Analysis by
Clinical Stage Development, H2 2014
13Comparative Analysis by Early Stage
Development, H2 2014 14Products under
Development by Companies, H2 2014 15Primary
Biliary Cirrhosis - Pipeline by AlbireoPharma, H2
2014 16Primary Biliary Cirrhosis - Pipeline by
Dr. Falk Pharma GmbH, H2 2014 17Primary Biliary
Cirrhosis - Pipeline by GlaxoSmithKline plc, H2
2014 18Primary Biliary Cirrhosis - Pipeline by
Intercept Pharmaceuticals, Inc., H2 2014
19Primary Biliary Cirrhosis - Pipeline by
Johnson Johnson, H2 2014 20Primary Biliary
Cirrhosis - Pipeline by MediGene AG, H2 2014
21Primary Biliary Cirrhosis - Pipeline by NGM
Biopharmaceuticals, Inc., H2 2014 22Primary
Biliary Cirrhosis - Pipeline by Shire Plc, H2
2014 23Primary Biliary Cirrhosis - Pipeline by
Virobay Inc., H2 2014 24
7List of Figures
- Number of Products under Development for Primary
Biliary Cirrhosis, H2 2014 8Number of Products
under Development for Primary Biliary Cirrhosis -
Comparative Analysis, H2 2014 9Number of
Products under Development by Companies, H2 2014
10Comparative Analysis by Clinical Stage
Development, H2 2014 13Assessment by Monotherapy
Products, H2 2014 25Number of Products by Top 10
Targets, H2 2014 26Number of Products by Stage
and Top 10 Targets, H2 2014 27Number of Products
by Top 10 Mechanism of Actions, H2 2014 28Number
of Products by Stage and Top 10 Mechanism of
Actions, H2 2014 29Number of Products by Top 10
Routes of Administration, H2 2014 30Number of
Products by Stage and Top 10 Routes of
Administration, H2 2014 31Number of Products by
Top 10 Molecule Types, H2 2014 32Number of
Products by Stage and Top 10 Molecule Types, H2
2014 33
8Related Reports
- Fabry Disease-Pipeline Insights, 2015
- Ocular Hypertension-Pipeline Insights, 2015
- Fallopian Tube Cancer-Pipeline Insights, 2015
- Ocular Inflammation-Pipeline Insights, 2015
- Familial Adenomatous Polyposis Coli-Pipeline
Insights, 2015 - Ocular Pain-Pipeline Insights, 2015
- Oligodendroglioma-Pipeline Insights, 2015
- Familial Chylomicronemia (Type I
Hyperlipoproteinemia)-Pipeline Insights, 2015
9Follow Us
https//www.facebook.com/aarkstoredotcom
https//twitter.com/aarkstore
https//plus.google.com/Aarkstoredotcom/posts
https//www.linkedin.com/company/aarkstore-enterpr
ise
10Contact Us
Office Address Office No. - 809, 8th
Floor,B-Wing, Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Mail us at
contact_at_aarkstore.com 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953